Syndax Pharmaceuticals (SNDX) Cash & Equivalents (2015 - 2026)

Syndax Pharmaceuticals' Cash & Equivalents history runs 12 years deep, the most recent figure standing at $130.9 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 15.0% year-over-year to $130.9 million in Q1 2026; TTM through Mar 2026 was $130.9 million, a 15.0% decrease from a year earlier, with the FY2025 full-year figure at $134.9 million, down 12.43% from the prior year.
• Cash & Equivalents slipped to $130.9 million in Q1 2026 per SNDX's latest filing, from $134.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $295.4 million in Q4 2023 and bottomed at $57.5 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $116.8 million (2025), against an average of $126.6 million.
• Biggest YoY gain for Cash & Equivalents was 297.27% in 2023; the steepest drop was 69.53% in 2023.
• Year by year, Cash & Equivalents stood at $74.4 million in 2022, then jumped by 297.27% to $295.4 million in 2023, then plunged by 47.84% to $154.1 million in 2024, then decreased by 12.43% to $134.9 million in 2025, then decreased by 2.99% to $130.9 million in 2026.
• Per Business Quant, the three latest SNDX Cash & Equivalents figures stand at $130.9 million (Q1 2026), $134.9 million (Q4 2025), and $116.8 million (Q3 2025).